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Integrated lipidomics 
and proteomics reveal cardiolipin 
alterations, upregulation 
of HADHA and long chain fatty 
acids in pancreatic cancer stem 
cells
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Pancreatic cancer stem cells (PCSCs) play a key role in the aggressiveness of pancreatic ductal 
adenocarcinomas (PDAC); however, little is known about their signaling and metabolic pathways. 
Here we show that PCSCs have specific and common proteome and lipidome modulations. PCSCs 
displayed downregulation of lactate dehydrogenase A chain, and upregulation of trifunctional enzyme 
subunit alpha. The upregulated proteins of PCSCs are mainly involved in fatty acid (FA) elongation and 
biosynthesis of unsaturated FAs. Accordingly, lipidomics reveals an increase in long and very long‑
chain unsaturated FAs, which are products of fatty acid elongase‑5 predicted as a key gene. Moreover, 
lipidomics showed the induction in PCSCs of molecular species of cardiolipin with mixed incorporation 
of 16:0, 18:1, and 18:2 acyl chains. Our data indicate a crucial role of FA elongation and alteration in 
cardiolipin acyl chain composition in PCSCs, representing attractive therapeutic targets in PDAC.
Abbreviations
PDAC  Pancreatic ductal adenocarcinoma
PCSCs  Pancreatic cancer stem cells
CSCs  Cancer stem cells
HADHA  Hydroxyacyl-CoA dehydrogenase subunit alpha, trifunctional enzyme
CL  Cardiolipin
FA  Fatty acid
Pancreatic cancer comprises different types of neoplasia, among which the most common is the infiltrating neo-
plasm named pancreatic ductal adenocarcinoma (PDAC). PDAC arises in exocrine glands of the  pancreas1,2 and 
characterises 85% of pancreatic cancer cases. It represents the eleventh most common cancer  worldwide3 and the 
seventh leading cause of cancer-related deaths in the world, being on track to become the second most common 
cause of cancer-related deaths by  20301. It is the most lethal cancer with a 5-year survival rate of less than 9%4. 
PDAC is defined as an intractable malignancy for several reasons, but mainly due to lack of early diagnosis and 
effective treatments. Increasing evidence suggests that drug resistance and metastatic capability of PDAC are 
mainly influenced by the presence of highly plastic stem cells within the tumour, known as pancreatic cancer 
stem cells (PCSCs). PCSCs, described for the first time in  20075, represent a small (less than 1%) sub-population 
of undifferentiated quiescent  cells6 characterized by self-renewal, unique plasticity and metabolism, and capacity 
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to organize the tumour bulk producing a hierarchy of differentiated  cells7. Currently, the origin of cancer stem 
cells (CSCs) is still unknown. Two interrelated models have been proposed to explain the heterogeneity, chem-
oresistance, and aggressiveness of pancreatic  cancer8. Firstly, the hierarchical model that proposes CSCs as 
“entities” driving tumour formation, metastasis, chemoresistance, and relapse. Secondly, the stochastic model 
that describes CSCs as “states”, i.e. they can originate from all cancer cells because of accumulated mutations 
or epigenetic changes. PCSCs are characterized by aberrant expression of the embryonic stem cell transcrip-
tion factors, including Oct3/4, Nanog, and  Sox29,10, as well as of epithelial-to-mesenchymal transition markers, 
including CDH1 and  Zeb16. Recently, by proteomic and metabolomic profiling, our group reported that PCSCs 
obtained from Panc-1 PDAC cell line rely on fatty acid and mevalonate pathways for their  survival11. However, 
therapies targeting cancer-associated biosynthetic pathways have not given satisfactory results on overall patient 
 survival12, since these do not target either the plastic PCSC sub-population or the transient cells that replenish 
the PCSC  pool8.
Despite the importance of a multi-omics characterization of PCSC, in-depth characterization is still deficient. 
In addition to our previous  findings11,13 few  metabolomics14 and  proteomics15–17 studies have been published, 
while no lipidomic analysis has as yet been carried out on PCSCs. Further elucidation of the signaling path-
ways that regulate PCSC growth, survival, and metabolomic plasticity is needed to detect therapeutic targets 
and to explore novel therapeutic approaches against pancreatic  cancer18. Therefore, in the current study pro-
teomic and lipidomic analyses were integrated to investigate the signaling and metabolic dysfunctions impli-
cated in the pathophysiology of PCSCs obtained from parental (P) PDAC cell lines. Protein and lipid profiles 
of PCSCs derived from four PDAC cell lines harbouring different genetic  backgrounds19, e.g. PaCa3 (p16-met), 
PaCa44  (KRASG12V,  p53C176S, p16-met), MiaPaCa2  (KRASG12C,  p53R248W, p16-del), and PC1J  (KRASG12V,  p53R175H, 
SMAD4/DPC4D355G, p16-del) were analysed. To our knowledge, the current work presents the first proteome and 
lipidome investigation of PaCa3, PaCa44, MiaPaCa2, and PC1J CSCs obtained from relative PDAC cell lines. 
The results shown here support the potential of a multiomic approach and contribute to the understanding of 
PDAC biology revealing mitochondrial cardiolipin remodelling, as well as enhanced fatty acid elongation and 
phosphoinositol phosphatase pathways, as promising targets in PCSCs.
Results
PCSCs derived from the four cell lines show different morphological properties. Considering 
that cancer stem cells grow as spherical  formations20, the morphological differences between the four PCSCs and 
P cell lines (PaCa3, PaCa44, MiaPaCa2 and PC1J) were initially investigated. Different growth patterns between 
P and PCSCs were observed (Fig. 1a), with differences in the shape and size of cells. On one hand, the four P cell 
lines grew as adherent cells in monolayers showing an epithelial morphology with intact cell-to-cell contacts. 
On the other hand, PCSCs acquired a mesenchymal morphology forming tumour-spheroids in suspension with 
features that could depend on the cell line of origin.
PCSCs’ expression of stem and quiescent markers. mRNA levels of genes related to stemness (i.e. 
OCT3/4, SOX2, and NANOG), cell cycle (CYCLIN B1) and Wnt signaling (FRIZZLED 2, FZD2) were evaluated. 
Figure 1b shows that OCT3/4, SOX2 and NANOG genes were upregulated in PaCa3, PaCa44, and MiaPaca2 
CSCs compared to their respective P cell lines. However, no significant (p < 0.05) mRNA level differences of 
stemness genes were detected for PC1J CSCs. Therefore, protein expression of CSC markers was evaluated by 
immunoblotting in the four P cells and PCSCs. The results show that Oct3/4 was not detectable in either PCSCs 
or P cells (data not shown); whilst Sox2 and Nanog were induced in PaCa3, PaCa44, and PC1J CSCs. Moreover, 
not observable levels were established in MiaPaCa2 for both P and CSC cell lines (Fig. 1c). The mRNA expres-
sion of CYCLIN B1 and FRIZZLED 2 (FZD2) genes was also investigated (Fig. 1d). The results showed a decrease 
of CYCLIN B1, and an increase of FZD2 in all the four PCSCs compared to P cell lines.
PCSCs show upregulation of HADHA and dysregulated lipid‑metabolism‑related path‑
ways. Possible dysregulated signaling and metabolic pathways of PCSCs were investigated by performing 
proteomics and lipidomics analyses. Comparing the quantitative proteome levels between PCSCs and P cells 
revealed a total of 121, 186, 212, and 235 proteins differentially expressed in PaCa3, PaCa44, MiaPaCa2, and 
PC1J CSCs, respectively (Supplementary Table  S1). Dysregulated proteins among the different PCSCs were 
examined and are presented in a Venn diagram in Fig. 2a. Six proteins emerged as dysregulated in all the four 
PCSCs, where trifunctional enzyme subunit alpha (HADHA, aka hydroxyacyl-CoA dehydrogenase subunit 
alpha) and voltage-dependent anion-selective channel protein 2 (VDAC2) were upregulated. In contrast, hetero-
geneous nuclear ribonucleoprotein A/B Isoform 2 (HNRNPAB) and L-lactate dehydrogenase A chain (LDHA) 
had a lower expression in all the PCSCs compared to P cells. LDHA and HADHA modulation was also moni-
tored by immunoblotting (Fig. 2b). Western blot results indicated that LDHA and p-LDHA were downregulated 
in PCSCs, whilst HADHA upregulation was detected in MiaPaca2 and PC1J CSCs. Proteomics results revealed 
that upregulated proteins of PCSCs were mainly mitochondrial proteins and are particularly involved in meta-
bolic pathways and lipid metabolism (Supplementary Table S2). The significantly enriched KEGG pathways (p 
value < 0.05) of upregulated proteins in PCSCs related to lipid metabolism, including FA elongation and biosyn-
thesis of unsaturated FAs, are reported in Fig. 2c. In particular, the pathways in which HADHA is involved are 
indicated by an asterisk.
PCSCs display induction of long chain fatty acids and lipid droplets. The lipid profile of all four 
pairs of PCSCs and P cells was obtained, and a total of 755 lipid species were quantified. Principal component 
analysis (PCA) of the fold-change of PCSCs/P ratio showed that all the cell lines cluster away from each other 
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Figure 1.  PCSCs grow as spheroids and have dysregulated levels of stemness and quiescence related markers. 
(a) Bright-field microscopy of P cells (upper lane) and PCSCs (bottom lane) obtained after 2 weeks of culture 
(× 20 magnification). Scale bar = 50 and 25 μm for P cells and PCSCs, respectively. (b) Histogram representation 
of q-PCR analysis of OCT3/4, SOX2, and NANOG gene expressions. (c) Immunoblotting assay of Sox2 and 
Nanog protein expressions. The blots were cropped to focus upon the specific proteins indicated. The full-length 
blots are presented in Supplementary Figure S1. (d) Histogram representation of q-PCR analysis of mRNA 
expression of cyclin B1 and FZD2 gene expressions. Results are reported as means ± standard error (SE) of three 
independent biological replicates; p < 0.05 (*), p < 0.01 (**), p < 0.001 (***), p < 0.0001 (****).
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(Fig. 3a) indicating that certain discriminating features are detectable at the lipid level. Lipid subclasses and spe-
cies dysregulated in PCSCs are all reported in Supplementary Table S3 and Supplementary Figure S2. The results 
show a general increase in FAs in PCSCs as compared to P cells. Modulation of FA intracellular levels were evalu-
ated in PCSCs and P cells by a colorimetric enzymatic assay, showing the statistically significant (p < 0.05) accu-
mulation of FAs in Paca44, MiaPaca2, and PC1J CSCs (Fig. 3b). Although a trend of increase was also detected in 
Paca3 CSCs. The FA results obtained by LC–MS showed a trend towards increased levels of long (16–20 carbons) 
and very long (≥ 22 carbons) chain FAs in PCSCs as compared to P cells (Fig. 3c).
Figure 2.  PCSCs display downregulated LDHA, upregulated HADHA, and some specific lipid pathways 
dysregulated. (a) Venn diagram of identified proteins dysregulated in PCSCs in comparison to P cells in the four 
cell lines (p value ≤ 0.05; fold change ± 1.5). (b) Immunoblotting assay of HADHA, LDHA and p-LDHA proteins. 
β-actin was used as a loading control in Western blot analysis. The blots were cropped to focus upon the specific 
proteins indicated. The full-length blots are presented in Supplementary Figure S1. (c) The significantly enriched 
KEGG pathways (p value < 0.05) of the upregulated proteins in PCSCs that are related to lipid metabolism. The 
asterisk indicates the pathways in which HADHA is involved.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:13297  | https://doi.org/10.1038/s41598-021-92752-5
www.nature.com/scientificreports/
Figure 3.  Accumulation of fatty acids and lipid droplets in PCSCs. (a) Principal component analysis (PCA) 
of lipid profile of PaCa3, PaCa44, MiaPaCa2, and PC1J CSCs against P cells. Analysis of FAs as detected by (b) 
FFA Quantification kit and (c) LC–MS/MS-based lipidomics (bars show mean fold change ± 95% confidence 
intervals). (d) Representative confocal microscopy images of PCSCs and P cells labelled with Oil Red O (red) 
to detect LDs, and with DAPI (blue) to highlight nuclei. Measure of (e) number and (f) size (as volume, μm3) of 
LDs obtained following imaging cells (data are presented as means ± standard error (SE) of three independent 
experiments); (g) analysis of CE + TG content (normalized on PC) detected by LC–MS/MS-based lipidomics 
(bars show mean fold change ± 95% confidence intervals). p < 0.05 (*) and p < 0.0001 (****).
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LC–MS results also showed an increase of some neutral lipids in PCSCs, therefore cells were imaged using 
confocal microscopy to evaluate lipid droplets (LDs) properties (Fig. 3d). A trend of induction, in either number 
(Fig. 3e) or volume (Fig. 3f) of LDs was detected in all the four PCSCs. Lipidomic analysis showed a trend of 
increased content of two major lipids of LDs, TG and CE, in all the PCSCs except for Paca3 CSCs (Fig. 3g) which, 
however, seems to be characterized by a greater number of LDs.
Phosphoinositide signaling and fatty acid elongation are peculiar pathways of PCSCs. The 
lipidomics analysis performed by BioPAN revealed active pathways and related genes for each PCSCs (Table 1). 
BioPAN combines current knowledge of lipid metabolism with a statistical analysis framework, by comparing 
two biological conditions to identify activated or suppressed pathways, and presents the results in an interac-
tive graphical display, ranking the reactions using Z-score values. Each gene activates or supresses enzymes 
catalysing lipid metabolic pathways (Supplementary Figure S3), and a Venn diagram representation was used to 
show overlapping between these genes (Fig. 4a). The results highlighted 14 common genes involved in pathways 
predicted as active in all four PCSCs compared to P cells. Among these, thirteen (i.e., SYNJ1, SYNJ2, SACM1L, 
MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, and PTEN) encode for 
phosphoinositide lipid phosphatase proteins, and one for the fatty acid elongase-5 (ELOVL5).
As concerning the substrates and the products of phosphoinositide lipid phosphatases, a statistically signifi-
cant increase (at 95% CI) in the levels of phosphatidylinositol (PI) in PaCa3, MiaPaCa2 and PC1J CSCs was 
observed (Fig. 4b). In addition, the levels of phosphatidylinositol monophosphate (PIP) appeared to be not 
statistically significant (at 95% CI) changed, whilst the levels of phosphatidylinositol diphosphate (PIP2) showed 
a 1.2 and two-fold statistically significant decrease in MiaPaCa2 and PC1J CSCs.
Based on the proteomics results, FA elongation and biosynthesis of unsaturated FAs emerged as key pathways 
for PCSCs, therefore the role of the elongases and desaturases was also investigated in the FA metabolism (Sup-
plementary Figure S4). Genes associated with the biosynthesis of FAs, among which ELOVL5, are also included in 
Table 1. As concerning products of the catalytic activity of Elovl5, a general increase in long and very long-chain 
unsaturated FAs was detected in PCSCs, with the exception of PaCa44 CSCs (Fig. 4c–f). In particular, statistically 
significant (at 95% CI) increased levels of FAs 18:1, 20:2, 20:3, 22:4 were detected in MiaPaca2 and PC1J CSCs, 
and of FA 20:4 in Paca3, MiaPaca2 CSCs.
PCSCs are characterized by alteration in cardiolipin acyl chain composition. CL molecular spe-
cies, which could contain fatty acyl chain incorporation of C18:1, C18:2, and C16:0 are shown in Fig. 4c–f. A 
trend of increase was observed in some CL molecular species of PCSCs. On the contrary, a statistically signifi-
cant decrease (95% CI) of 4.2-fold was only observed in CL 68:2 of PaCa3 CSCs (Fig. 4a). Interestingly, a statisti-
cally significant (95% CI) increase was observed in CL 64:0 (fivefold), CL 64:1 (5.5-fold), CL 66:1 (3.5-fold), and 
CL 66:5 (3.2-fold) in MiaPaCa2 CSCs (Fig. 4c). In addition, a fivefold a statistically significant increment in CL 
66:5 molecular species were detected in PC1J CSCs (Fig. 4d).
Discussion
PCSCs play a crucial role in PDAC initiation and metastasis and are responsible for resistance to chemotherapy 
and radiation, however these cells are still not completely characterized from a molecular point of view. Here 
we find that Sox2, Oct3/4 and Nanog are induced in PCSCs when compared to P cells. These transcriptional 
factors are key players in inducing stemness in cancer  cells21. Strangely, we detected increased Sox2 and Nanog 
expression at the protein level, but not at the mRNA level, in PC1J CSCs, which may be explained by different 
half-life and/or degradation rate of mRNAs in these cells as compared to the other PDAC cell lines. On the con-
trary, increased Sox2, Oct3/4 and Nanog expression at mRNA level, but not at the protein level, was detected 
in MiaPaca2 CSCs suggesting that stem cell markers of these cells may have undetectable expression under the 
experimental conditions or a modified epitope which preclude their immunodetection. Our results also show that 
PCSCs have reduced expression of cyclinB1 and induced expression FZD2 at mRNA level. Cyclin B1 plays a key 
role in the transition from the G2 to M phase of the mitotic process, suggesting a G2/M phase arrest of analysed 
PCSCs. Accordingly, it has been reported that some CSCs are slow-cycling quiescent  cells22, thus not dividing 
while retaining the ability to re-enter cell proliferation. Whilst the observed increase in FZD2 is in agreement 
with previously reported results that show Fzd2 involvement in the activation of Wnt signaling, a key regulating 
gene in  CSCs23 as well as in drug  resistance24. Moreover, Fzd2 has been proposed as a novel target for molecular 
therapy of pancreatic  cancer25.
Our comprehensive analysis of protein modulation in PCSCs and P cells portrays specific and common 
proteome changes for the four PCSCs, most of which are related to dysregulated lipid-metabolism pathways. 
Interestingly, among these latter are the biosynthesis and metabolism of cholesterol, the main product of the 
already reported mevalonate  pathway11. Currently, the debate on PCSC metabolism is still open, as some studies 
revealed PCSCs to be highly glycolysis-dependent6 while others point to oxidative phosphorylation (OXPHOS) 
 dependency26. LDHA was found downregulated in all the PCSCs, which is consistent with the OXPHOS as 
energy source in PCSCs rather than  glycolysis27. Moreover, LDHA phosphorylation of tyrosine in position 10 
was also evaluated by immunoblotting, as p-LDHA promotes the activity of LDHA and the Warburg  effect28, 
demonstrating a downregulation of p-LDHA in PCSCs.
To further dissect the metabolic pathways, a comprehensive analysis of lipid modulations in PCSCs and P 
cells was performed. The findings suggest that PCSCs are characterized by induction of long chain fatty acids 
and accumulation of lipid droplets. Phosphoinositide signaling and fatty acid elongation come off as specifically 
noteworthy pathways in PCSCs. Accordingly, some main genes involved in these pathways were detected: PTEN 
(among many other phosphoinositide lipid phosphatases) and ELOVL5. Pten has a dual-specificity phosphatase 
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Table 1.  BioPAN predicted significantly active reactions chains (Z > 1.645) of lipid class and FA species and 
relative genes for each reaction of PCSC lines.
Reaction chain Z-score Predicted genes
PaCa3 CSCs
SM → Cer 3.014 SMPD2, SMPD3
O-DG → O-PE → P-PE 2.612 CEPT1, TMEM189
PIP2 → PIP → PI 2.211 FIG4, OCRL, INPP5E, PTEN, SYNJ1, SYNJ2, SACM1L, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, PTEN
O-DG → O-PC 2.074 CHPT1
FA 16:1 → FA 18:1 → FA 20:1 → FA 22:1 → FA 24:1 1.834 ELOVL5, ELOVL6, ELOVL3, ELOVL3, ELOVL3
dhSM → dhCer 1.828 SGMS1, SGMS2
DG → PE 1.673 CEPT1
PC → PS 1.654 PTDSS1
PaCa44 CSCs
FA 16:1 → FA 18:1 → FA 18:2 2.721 ELOVL5, ELOVL6, FADS2
O-PE → P-PE 2.620 TMEM189
dhCer → Cer → SM 2.221 DEGS1, DEGS2, SGMS1, SGMS2, CERT1
O-DG → O-PC 2.022 CHPT1
FA 18:1 → FA 18:2 1.930 FADS2
dhCer → dhSM 1.919 SGMS1, SGMS2
O-DG → O-PE → P-PE → P-PC 1.895 CEPT1, TMEM189, PLD1
DG → PE 1.859 CEPT1
PS → PE 1.805 PISD
DG → PC 1.685 CHPT1
PIP → PI 1.667 SYNJ1, SYNJ2, SACM1L, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, PTEN
MiaPaCa2 CSCs
PIP2 → PIP → PI 3.731 FIG4, OCRL, INPP5E, PTEN, SYNJ1, SYNJ2, SACM1L, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, PTEN
PIP → PI 2.392 SYNJ1, SYNJ2, SACM1L, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, PTEN
dhCer → dhSM 2.103 SGMS1, SGMS2
Cer → SM 2.049 SGMS1, SGMS2, CERT1
PIP2 → DG 2.007 PLCB1, PLCB2, PLCB3, PLCB4, PLCD1, PLCD3, PLCD4, PLCE1, PLCG1, PLCG2
PA → DG 1.983 PLPP1, PLPP2, PLPP3
O-LPE → O-LPA 1.944 PLD1
PE → PC 1.941 PEMT
PG → CL 1.821 CRLS1
O-PE → P-PE → P-PC 1.811 TMEM189, PLD1
PA → PS 1.782 CDS1, PTDSS1
PE → PS 1.779 PTDSS2
FA 18:2 → FA 20:2 1.717 ELOVL5
PC1J CSCs
O-DG → O-PC 3.644 CHPT1
PIP2 → PIP → PI 3.129 FIG4, OCRL, INPP5E, PTEN, SYNJ1, SYNJ2, SACM1L, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, PTEN
PIP2 → DG → PE 2.879 PLCB1, PLCB2, PLCB3, PLCB4, PLCD1, PLCD3, PLCD4, PLCE1, PLCG1, PLCG2, CEPT1
FA 16:0 → FA 16:1 → FA 18:1 → FA 20:1 2.527 SCD3, ELOVL5, ELOVL6, ELOVL3
PIP2 → DG → PC → PA 2.378 PLCB1, PLCB2, PLCB3, PLCB4, PLCD1, PLCD3, PLCD4, PLCE1, PLCG1, PLCG2, CHPT1, PLD1, PLD2
FA 18:0 → FA 18:1 → FA 18:2 → FA 20:2 → FA 20:3 → FA 20:4 2.349 SCD1, FADS2, ELOVL5, FADS1, FADS1
DG → PC 2.343 CHPT1
PIP2 → DG → PA 2.265 PLCB1, PLCB2, PLCB3, PLCB4, PLCD1, PLCD3, PLCD4, PLCE1, PLCG1, PLCG2, DGKA, DGKB, DGKD, DGKE, DGKG, DGKH, DGKI, DGKK, DGKQ, DGKZ
PIP → PI 2.148 SYNJ1, SYNJ2, SACM1L, MTMR1, MTMR2, MTMR3, MTMR4, MTMR6, MTMR7, MTMR8, MTMR9, MTMR14, PTEN
FA 18:0 → FA 18:1 → FA 20:1 → FA 22:1 2.098 SCD1, ELOVL3, ELOVL3
DG → PE 2.022 CEPT1
FA 16:0 → FA 16:1 → FA 18:1 → FA 18:2 → FA 20:2 → FA 20:3 → FA 20:4 1.982 SCD3, ELOVL5, ELOVL6, FADS2, ELOVL5, FADS1, FADS1
O-DG → O-PE 1.949 CEPT1
PIP2 → DG → PC → CL 1.931 PLCB1, PLCB2, PLCB3, PLCB4, PLCD1, PLCD3, PLCD4, PLCE1, PLCG1, PLCG2, CHPT1, TAZ
FA 20:2 → FA 20:3 1.926 FADS1
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activity: protein and lipid dephosphorylation. As a lipid phosphatase, preferentially dephosphorylates phospho-
inositide substrates, removing the phosphate from phosphatidylinositol 3,4,5-trisphosphate (PIP3), PIP2, PIP and 
inositol 1,3,4,5-tetrakisphosphate (I4P)29,30. In contrast, Elovl5 plays a role in the addition of two carbon units 
to the carboxyl ends of fatty acyl CoA substrates, acting on monounsaturated palmitoleoyl-CoA (C16:1)31 and 
linoleoyl-CoA (C18:2), and participating in the production of very long chain FAs 20:3, 20:4, 22:4 and 22:532,33.
Interestingly, lipid biosynthetic pathway analysis did not show genes in reaction pathways involving Car-
diolipin (CL) as no increased levels were detected; despite the fact that proteomics showed an upregulation of 
HADHA in all the four PCSCs, and a significant enrichment of “acyl chain remodelling of CL” pathway for CSCs 
derived from MiaPaca2 and PC1J cells. CL is a major mitochondrial membrane glycerophospholipid  subclass34 
and comprises two diacylglycerol phosphate residues connected by a glycerol backbone and four fatty acyl chains. 
CL is derived from the catalytic activity of Cardiolipin synthase (CRLS) on two units of phosphatidylglycerol 
(PG), but activity of the phospholipase A2 produces monolysocardiolipin, which is the substrate for HADHA. 
Therefore, fatty acyl chain combinations in CL give a wide variety of mature CL species. On the one hand 
HADHA catalyses the last three steps of mitochondrial β-oxidation of FAs, when is accompanied by the β subunit 
(HADB)35. On the other hand, HADHA plays a role in the acylation of monolysocardiolipin to form  CL36,37. Thus, 
further analysis of the CL lipid molecular species linked with CL remodelling by HADHA were performed. Our 
lipidomic analysis indicated, for MiaPaCa2 and PC1J CSCs, increased levels of CL molecular species showing 
incorporation of oleoyl-CoA (C18:1), linoleoyl-CoA (C18:2), and palmitoyl-CoA (C16:0). However, not direct 
correlation can be suggested with CL results and HADHA upregulation.
It has been reported that changes in CL molecular species composition has an enormous impact on the 
structural integrity of the inner membrane of mitochondria and on the enzymatic activity of all mitochondrial 
respiratory  complexes38,39. These protein complexes can be linked with oxidative stress modulation by reduction 
of superoxide levels, proton pump homeostasis, and energy  metabolism40. Therefore, CL plays a critical role in 
oxidative phosphorylation (OXPHOS). During this process, many protons are transported across the mito-
chondrial membrane, causing a pH shift. In this context, CL molecular species function as a proton trap within 
the membranes of this  organelle41. Mechanistically,  H+ ions interact with  PO4− groups of CL to neutralize its 
negative charge and to reduce the size of the hydrate coat around the polar  head42. The neutralized CL acquires 
a reverse molecular shape, a non-bilayer packing of CL results, and this leads to inverted micelles accumulating 
near highly-protonated regions of membranes. These non-bilayer structures favour the oligomerization of the 
F0 sector of the ATP synthase complex and act as a proton trap to shuttle protons to the ATP synthase complex 
leading to enhanced energy  production42,43. Very little recently published research have shown a prominent 
role for CL alterations in cancer stem cells. Interestingly, it has been shown that inhibition of mitochondrial 
phospholipid production, such as CL, reduces stemness and increases differentiation of acute myeloid leukaemia 
 cells44,45. To the best of our knowledge, this is the first time that the changes in CL acyl-chain composition have 
been demonstrated for a solid tumour like PDAC as well as its PCSCs.
In conclusion, a proteomic and lipidomic analysis of pancreatic parental cancer cells and cancer stem cells 
established major differences in the signaling and lipid metabolic pathways between these two cell types. In sum-
mary, the data obtained in this multiomics study showed that alteration of cardiolipin acyl-chain composition, 
fatty acid elongation, and phosphoinositide signaling are specific pathways of PCSCs and potential new targets 
in novel therapeutic strategies for pancreatic cancer.
Materials and methods
Cell culture. The human PDAC cell lines PaCa3, PaCa44, MiaPaCa2, and PC1J, called parental (P) cells, 
were obtained from American Type Culture Collection (ATCC). These cells were grown in RPMI 1640 media 
supplemented with 10% foetal bovine serum, 2 mM glutamine, and 50 µg/ml gentamicin sulphate (Gibco, Life 
Technologies). Cells were maintained at 37  °C with 5%  CO2 for some passages. As previously described by 
Dalla Pozza et al.46, PCSCs were obtained by growing adherent cells in “CSC medium” (i.e. DMEM/F-12, B27, 
1 g/l glucose, fungizone, penicillin/streptomycin, heparin, epidermal growth factor and fibroblast growth factor) 
for 2 weeks. “CSC medium” was refreshed twice a week with new medium solution and maintained at 37 °C with 
5%  CO2. PCSCs were passed through a cell strainer (> 40 μm) to separate cell spheres, followed by examination 
under a light microscope (Axio Vert. A1, Zeiss) at 20 × and 40 × magnifications, prior to spheres collection. The 
cell numbers and viabilities of P cells and PCSCs were determined with the trypan blue exclusion test. Cells with 
viability higher than 85% were pelleted, frozen with liquid nitrogen, and stored at − 80 °C for further analyses.
RNA extraction and qPCR. Total RNA was extracted from 1 ×  106 cells (PaCa3, PaCa44, MiaPaCa2, and 
PC1J parental and stem cells) using TRIzol Reagent (Life Technologies) according to the manufacturer’s instruc-
tions. The extracted RNA was quantified by NanoDrop One (Thermo Fisher Scientific) and checked for integ-
rity loading on 1.5% agarose gel. 1 μg of RNA was reverse transcribed using first-strand cDNA synthesis. The 
real-time PCR reaction was performed according to the protocol of the SYBR-Green detection chemistry with 
GoTaq qPCR Master Mix (Promega) on a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific). The 
sequence of the primers used in this experiment are provided in Supplementary Table S4. The cycling conditions 
used were: 95 °C for 10 min, 40 cycles at 95 °C for 15 s, 60 °C for 1 min, 95 °C for 15 s, and 60 °C for 15 s. Reac-
tions were run in triplicate in three independent biological experiments. Expression data were normalized on 
the housekeeping SDHA and were analysed using the  2−ΔΔCT method.
Protein extraction and LC–MS/MS proteomics analysis. Identification and quantification of pro-
teome modulation of P cells and CSCs of the four cell lines were performed as previously reported by Brandi 
et al.47. Briefly, cells were collected (three biological replicates for each cell type), washed and lysed in 1X PBS 
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Figure 4.  Increased levels of phosphatidylinositol, fatty acids and cardiolipin molecular species characterize 
PCSCs. (a) Venn diagram representation of genes implicate in active lipid pathways found using BioPAN. (b) 
 Log2 ratio (PCSC/P) in the four PDAC cell lines of the values of phosphatidylinositol diphosphate (PIP2), 
phosphatidylinositol monophosphate (PIP), and phosphatidylinositol (PI).  Log2 ratio (PCSC/P) in (c) PaCa3, 
(d) PaCa44, (e) MiaPaCa2, and (f) PC1J cells of the FA substrates and products catalysed by Elovl5, including 
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with protease inhibitors cocktail and 0.1% SDS. Acetone was used for protein precipitation/denaturation fol-
lowed by resuspension in 100 mM  NH4HCO3. Protein content was measured by Bicinchoninic Acid Protein 
Assay. Thirty µg of protein extract was subjected to reduction (with dithiothreitol) and alkylation (with iodoacet-
amide), prior to tryptic digestion at 37 °C overnight.
Tryptic peptides were analysed by label-free LC–MS/MS as  previously48, performed by using a micro-LC 
system (Eksigent Technologies, Dublin, USA) interfaced with a 5600 + TripleTOF mass spectrometer (AB SCIEX, 
Concord, Canada). Samples were subjected first to data-dependent acquisition (DDA) analysis to generate the 
SWATH-MS spectral library, and then to cyclic data independent analysis (DIA), based on a 25-Da window, 
using three technical replicates of each sample. The MS data were acquired by Analyst TF v.1.7 (AB SCIEX), 
while PeakView v.1.2.0.3, Protein Pilot v.4.2 (AB SCIEX) and Mascot v.2.4 (Matrix Science) programs were used 
to generate the peak-list. The database search was performed using the UniProt/Swissprot (v.2018.01.02, 42271 
sequences entries). Samples were input in the Protein Pilot software v. 4.2 (AB SCIEX, Concord, Canada), with 
the following parameters: cysteine alkylation, digestion by trypsin, no special factors and FDR at 1% were used 
for database search with Protein Pilot, while for Mascot search the following parameters were used: trypsin as 
digestion enzyme, 2 missed cleavages, search tolerance of 50 ppm for the peptide mass tolerance and 0.1 Da for 
the MS/MS tolerance. The charges of the peptides to search for were set to 2 +, 3 + and 4 +, and the search was 
set on monoisotopic mass. The instrument was set to ESI-QUAD-TOF and the following modifications were 
specified for the search: carbamidomethyl cysteines as fixed modification and oxidized methionine as variable 
modification. FDR was fixed at 1%. Peak lists generated by both Protein Pilot and Mascot were compared to 
UniProt/Swissprot (v.2018.01.02, 42271 sequences entries) database. The obtained files from the DDA acquisi-
tions were used for the library generation using a FDR threshold of 1%. Protein quantification was performed 
by PeakView v.2.0 and MarkerView v.1.2. (AB SCIEX) programs by extracting from SWATH files ten peptides 
per protein with the highest MS1 intensity, and ten transitions per peptide. Peptides with FDR lower than 1.0% 
were exported, and up- and downregulated proteins were selected using p value < 0.05 and fold change > 1.5.
Lipid extraction and LC–MS/MS lipidomics analysis. Lipids extraction and analysis was performed 
as previously  outlined49. Briefly, frozen cell pellet lipids were extracted using the Folch method with Chloro-
form/Methanol/Water (2:1:1 ratio). Lipids were dried using a SpeedVac (Savant SP131DDA, Thermo Scientific, 
Runcorn, UK) and re-suspended in Chloroform/Methanol (1:1), prior to injection into a Shimadzu Prominence 
20-AD system (Shimadzu, Kyoto, Japan). Chromatographic separation was achieved using a Waters Acquity 
UPLC C4 (100 × 1 mm, 1.7 μm particle size) column (Milford, MA, U.S.A.). The column was kept a 45 °C and 
7 μl of samples were eluted using a mobile phase composed of solvent A (water) and B (acetonitrile), each con-
taining 0.025% formic acid. The gradient started at 45% B for 5 min, then increased to 90% B for 5 min, and 
100% B was reached after an additional 10 min and held for 7 min before re-equilibration at 45% B for 5 min. The 
flow rate was maintained at 100 μl/min. Accurate mass (with an error below 5 ppm) was acquired on an Orbitrap 
Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Source parameters for positive polarity 
were: capillary temperature 275 °C; source heater temperature 200 °C; sheath gas 10 AU; aux gas 5 AU; sweep 
gas 5 AU. Source voltage was 3.8 kV. Full scan spectra in the range of m/z 340–1500 were acquired at a target 
resolution of 240,000 (FWHM at m/z 400). Manual inspection of the results was carried out using Xcalibur and 
further processed using Lipid Data Analyzer (LDA) 2.7.0_2019  software50.
Targeted analysis of lysolipids, Cer, and dhCer, was performed using a QTRAP 6500 LC–MS/MS System 
(AB SCIEX) operating in MRM mode. Quantification of multiple species of ceramides was carried out by the 
integration of the peak area as normalized against the peak area of the non-endogenous odd-chain ceramide 
C17:0. C17 was present at a known concentration and served as the internal standard (IS). Collision energy (CE) 
was optimized previously.
Thirtyfive lipid subclasses were identified, including alkenyl-acylphosphatidylcholine (P-PC), alkenyl-
acylphosphatidylethanolamine (P-PE), alkyl-acylglycerol (O-DG), alkyl-acylphosphatidylcholine (O-PC), 
alkyl-acylphosphatidylethanolamine (O-PE), alkyl-triacylglycerol (O-TG), cardiolipin (CL), ceramides (Cer), 
cholesterol (CH), cholesterol ester (CE), diacylglycerol (DG), dihydroceramides (dhCer), dihydrosphingomyelin 
(dhSM), free fatty acids (FA), phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylglycerol (PG), phosphatidylinositol (PI), phosphatidylserine (PS), sphingomyelin (SM), sphingosine 
(SG), triacylglycerol (TG), lysophosphatidic acid (LPA), lysophosphatidylcholine (LPC), lysophosphatidyletha-
nolamine (LPE), lysophosphatidylglycerol (LPG), lyso phosphatidylinositol (LPI), phosphatidylserine (LPS), 
alkenyl-lysophosphatidylcholine (P-LPC), alkenyl-lysophosphatidic acid (P-LPA), alkyl-lysophosphatidyleth-
anolamine (O-LPE), alkyl-lysolysophosphatidylcholine (O-LPC), phosphatidylinositolmonophosphate (PIP), 
phosphatidylinositoldiphosphate (PIP2), phosphatidylinositoltriphosphate (PIP3).
Lipid relative quantitation levels were calculated using the R-studio (v3.2.4)  software51 (https:// www.R- proje 
ct. org) with in-house built scripts. Statistical comparison between the P cells and PCSCs was performed using 
the paired t-test (p < 0.005), principal component analysis (PCA), and  log2 ratio transformation of PCSCs versus 
parental lipid levels.
Bioinformatics analysis of omics data. Bioinformatics analysis of proteomic data was performed as 
previously  described52. Briefly, to characterize the function of proteins, gene ontology (GO) annotation, KEGG 
and Reactome pathways enrichment analyses were performed using STRING v.11.0 (http:// string- db. org)53. The 
differentially expressed proteins were analysed for candidate functions and pathways enrichment, setting Homo 
sapiens as taxonomy, p < 0.05 and gene count > 2 as cut-off point.
Lipid profile levels obtained from the four PCSCs and P cells were loaded into an open access tool BioPAN, 
on LIPID MAPS Lipidomics Gateway (https:// lipid maps. org/ biopan/)54. BioPAN provides Z-scores (Z > 1.645 
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at p < 0.05) using substrate and product lipid levels and integrate a list of genes, which could be involved in the 
activation or suppression of enzymes catalysing lipid metabolic pathways.
Western blot analysis. Western Blot analysis was performed as previously  described55. Briefly, proteins 
were resolved on 12% SDS–PAGE gels and transferred to PVDF membrane. After transferring proteins onto 
PVDF membranes, Amido Black 1X Staining Solution was used to confirm equal protein loading in different 
lanes. The membranes were blocked with 5% non-fat dry milk in 0.1% Tris-buffered saline (TBS)/Tween-20 and 
incubated with primary antibodies diluted as reported in Supplementary Table S5, at 4 °C overnight. Once incu-
bation with secondary antibodies was carried out, detection by enhanced chemiluminescence was performed. 
The chemiluminescent signal was acquired through a ChemiDoc MP Imager (Bio-Rad) using the Image Lab 
5.2.1 software (Bio-Rad).
Confocal fluorescence microscopy. CSCs and P cells were grown on a L-lysine coverslip inside a 24-well 
plate and incubated at 37 °C (5%  CO2) for lipid droplets (LDs) staining. Supernatant was removed and, after 
washing with PBS, cells were fixed using 8% formaldehyde, for 10 min at room temperature. After fixation and 
washing, cells were incubated with Oil Red O (Bio-Optica) for 20 min at room temperature. Thus, cells were 
washed again, treated with 0.1% Triton X-100 and 1% bovine serum albumin for 15 min at room tempera-
ture, and stained with DAPI (4′,6-diamidino-2-phenylindole nuclei stain, dilution 1:1000; Sigma Aldrich) for 
30 min for nuclei visualization. Samples were scanned by a confocal microscope (Leica TCS SP5 AOBS) using 
416 nm and 545 nm lasers under a 40 × oil objective. The images were analysed using Leica Application Suite X 
3.7.0.20979 software. Imaris X64 9.1.0 software to generate z- and three-dimensional projections for the analysis 
of lipid LDs shape and volume. Twenty images per sample were recorded and LDs were counted manually using 
the ImageJ multipoint tool after background correction. Detected LDs were normalized per cell nucleus. Statisti-
cal analysis (t-test) was performed to identify significant changes.
Assessment of free fatty acids levels. The levels of free fatty acid were determined using a FFA Quan-
tification Kit (MAK044, Sigma Aldrich) according to the manufacturer’s instructions. Briefly, cells were lysed 
in 1% Triton X-100 in chloroform (w/v) and centrifuged at 13,000 × g for 10 min to remove insoluble debris. 
The organic phase was collected, dried on 50 °C dry bath for 20 min, fatty acid assay buffer was added and then 
dissolved by extensive vortex mixing. After that, absorbances for individual wells were read at 570 nm using a 
microplate reader, and values reported as μM FFA/million cells.
Data availability
Data are available via ProteomeXchange with identifier PXD023069, username: reviewer_pxd023069@ebi.ac.uk, 
password: HE4R6eQ3.
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